marianvejcik / iStockphoto.com
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate (SPC) because it failed to meet the standards set out by Europe’s highest court earlier this year.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
supplementary protection certificate, SPC, patent, HIV, generics, Truvada, English High Court, Mr Justice Arnold, Gilead, Teva, Accord Healthcare, Mylan